|  |  |  | **Trimester** | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **T1** | | **T2** | | **T3** | |
|  |  |  | **Exposed** | | | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 877 | 874 | 1,288 | 1,293 | 818 | 816 |
| Age | - | Median [Q25 - Q75] | 33.00 [30.00 - 37.00] | 33.00 [30.00 - 37.00] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] | 35.00 [31.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 44 (5.0%) | 47 (5.4%) | 48 (3.7%) | 48 (3.7%) | 17 (2.1%) | 14 (1.7%) |
|  | 25 to 39 | N (%) | 743 (84.7%) | 741 (84.8%) | 1,096 (85.1%) | 1,100 (85.1%) | 707 (86.4%) | 705 (86.4%) |
|  | 40 to 55 | N (%) | 90 (10.3%) | 86 (9.8%) | 144 (11.2%) | 145 (11.2%) | 94 (11.5%) | 97 (11.9%) |
| Vaccine brand | Moderna | N (%) | 649 (74.0%) | 645 (73.8%) | 917 (71.2%) | 917 (70.9%) | 520 (63.6%) | 524 (64.2%) |
|  | Pfizer | N (%) | 228 (26.0%) | 229 (26.2%) | 371 (28.8%) | 376 (29.1%) | 298 (36.4%) | 292 (35.8%) |
| Trimester | Trimester 1 | N (%) | 877 (100.0%) | 874 (100.0%) | - | - | - | - |
|  | Trimester 2 | N (%) | - | - | 1,288 (100.0%) | 1,293 (100.0%) | - | - |
|  | Trimester 3 | N (%) | - | - | - | - | 818 (100.0%) | 816 (100.0%) |
| Number visits prior year | - | Median [Q25 - Q75] | 13.00 [6.00 - 24.00] | 22.00 [10.00 - 42.00] | 20.00 [10.00 - 34.00] | 34.00 [18.00 - 54.00] | 26.00 [16.00 - 42.00] | 44.00 [26.00 - 68.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 163 (18.6%) | 170 (19.5%) | 251 (19.5%) | 220 (17.0%) | 166 (20.3%) | 171 (21.0%) |
|  | Heart conditions | N (%) | 14 (1.6%) | 16 (1.8%) | 40 (3.1%) | 40 (3.1%) | 23 (2.8%) | 16 (2.0%) |
|  | Eclampsia preeclampsia | N (%) | 7 (0.8%) | 11 (1.3%) | 12 (0.9%) | 12 (0.9%) | 11 (1.3%) | 13 (1.6%) |
|  | Asthma | N (%) | 48 (5.5%) | 55 (6.3%) | 71 (5.5%) | 88 (6.8%) | 54 (6.6%) | 56 (6.9%) |
|  | Pneumonia | N (%) | 22 (2.5%) | 25 (2.9%) | 36 (2.8%) | 33 (2.6%) | 22 (2.7%) | 19 (2.3%) |
|  | Hypothyroidism | N (%) | 67 (7.6%) | 73 (8.4%) | 120 (9.3%) | 136 (10.5%) | 75 (9.2%) | 97 (11.9%) |
|  | Depressive disorder | N (%) | 31 (3.5%) | 53 (6.1%) | 80 (6.2%) | 67 (5.2%) | 52 (6.4%) | 40 (4.9%) |
|  | Gestational diabetes | N (%) | 30 (3.4%) | 41 (4.7%) | 57 (4.4%) | 44 (3.4%) | 60 (7.3%) | 53 (6.5%) |
|  | Chronic hypertension | N (%) | 20 (2.3%) | 30 (3.4%) | 24 (1.9%) | 27 (2.1%) | 20 (2.4%) | 17 (2.1%) |
|  | Anxiety disorder | N (%) | 244 (27.8%) | 217 (24.8%) | 372 (28.9%) | 350 (27.1%) | 200 (24.4%) | 207 (25.4%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 28 (3.2%) | 28 (3.2%) | 45 (3.5%) | 31 (2.4%) | 29 (3.5%) | 12 (1.5%) |
|  | Progestogens | N (%) | 51 (5.8%) | 36 (4.1%) | 78 (6.1%) | 90 (7.0%) | 54 (6.6%) | 48 (5.9%) |
|  | Antimycotics systemic | N (%) | 6 (0.7%) | 7 (0.8%) | 5 (0.4%) | <5 (<5%) | <5 (<5%) | <5 (<5%) |
|  | Estrogens | N (%) | 60 (6.8%) | 65 (7.4%) | 75 (5.8%) | 66 (5.1%) | 38 (4.6%) | 35 (4.3%) |
|  | Antithrombotics | N (%) | 55 (6.3%) | 22 (2.5%) | 155 (12.0%) | 92 (7.1%) | 129 (15.8%) | 82 (10.0%) |
|  | Antihistamines systemic | N (%) | 104 (11.9%) | 109 (12.5%) | 207 (16.1%) | 251 (19.4%) | 142 (17.4%) | 127 (15.6%) |
|  | Antidepressants | N (%) | 48 (5.5%) | 52 (5.9%) | 71 (5.5%) | 61 (4.7%) | 28 (3.4%) | 32 (3.9%) |
|  | Immunoglobulins | N (%) | <5 (<5%) | <5 (<5%) | 22 (1.7%) | 26 (2.0%) | 90 (11.0%) | 81 (9.9%) |
|  | Analgesics and antipyretics | N (%) | 239 (27.3%) | 238 (27.2%) | 469 (36.4%) | 443 (34.3%) | 329 (40.2%) | 289 (35.4%) |
|  | Antiinflammatory antirehumatic | N (%) | 202 (23.0%) | 237 (27.1%) | 217 (16.8%) | 180 (13.9%) | 70 (8.6%) | 71 (8.7%) |
|  | Antiepileptics | N (%) | 16 (1.8%) | 18 (2.1%) | 12 (0.9%) | 14 (1.1%) | 9 (1.1%) | 12 (1.5%) |
|  | Antibacterials systemic | N (%) | 169 (19.3%) | 149 (17.0%) | 287 (22.3%) | 254 (19.6%) | 185 (22.6%) | 186 (22.8%) |